The recurrence score assay stratifies early stage, estrogen receptor-positive breast cancer by recurrence risk. This study assessed how clinicians use the recurrence score to recommend adjuvant systemic therapy or patients' experiences with testing decision-making.
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
DNA methylation profiling identified the primary cancer in cases of cancer of unknown primary, informing tumor-type specific treatment that improved overall survival in these patients.
Applying evolutionary theory improves the accuracy of predicting in which patients Barrett's esophagus will progress to esophageal adenocarcinoma.
Precision medicine based on genetic makeup of tumors is leading to anticancer treatments that target specific patients; however, racial and ethnic minorities are underrepresented in genomic samples, resulting in less benefit from advances in cancer care for these patients.
The 70-gene signature test, in combination with standard clinical-pathologic criteria, may help clinicians decide whether patients with early stage breast cancer who are at high clinical risk require adjuvant chemotherapy.
ESR1 mutations are more frequent in patients with estrogen receptor (ER)-positive metastatic breast cancer that are treated with aromatase inhibitors, according to recent study data.
The National Cancer Moonshot needs to target proteins that are driving cancer rather than focusing only on genomics, a new paper suggests.
The geometric shape of the outside edge of a cancerous tumor plays a significant role in activating tumor-seeding cells that lead to metastasis.
Disparities in the gut microbiome between healthy people and women with estrogen-driven breast cancer may indicate possible biomarkers based on the microbiome that could help to mitigate the risk of certain cancers.
A nurse-managed precision cancer treatment education resource center may improve information dissemination about genomic health and targeted therapy.
[Biomarkers in Cancer] This research examines the emerging role of genomic rearrangements in breast cancer, with a particular focus on fusion genes, and explores the therapeutic value of such rearrangements and their significance as predictive and prognostic biomarkers.
Despite improvements in genomic sequencing technologies, a significant number of medically important genes are within genomic regions in which sequencing lacks the technical accuracy to generate reliable reads.
Participation in human research may improve with full disclosure and increased transparency of the risks of participating in publicly shared, big-data research projects.
Detailed new information about diffuse glioma has come from an international collaborative study, raising hopes for improved clinical outcomes from a better understanding of the disease.
Patients younger than 50 years with NSCLC were more likely to have a targetable genomic alteration for which therapies exist.
Genetic analyses and other tests performed by both researchers and physicians can be significantly skewed when normal cells, especially immune cells, are intermixed with cancerous cells in a tissue sample.
An international team mined RNA sequences to identify non-protein-coding segments whose expression is linked to 13 different types of cancer.
Genome sequencing database provides easy access to information on clinically important cancer gene mutationsSeptember 25, 2015
Researchers designed an online database, the Cancer Driver Log (CanDL) to help oncologists and other health care professionals identify key mutations that drive tumor growth in tissues.
Researchers identify tumor microenvironment of metastasis (TMEM) that allows breast cancer to metastasizeAugust 28, 2015
Using high-resolution imaging, scientists have gained a greater understanding of how a doorway in the blood vessel wall allows cancer cells to metastasize.
An international team has decoded the molecular characteristics of acute lymphoblastic leukemia (ALL), a cancer with some incurable subtypes.
DENVER, CO—The nurse navigator's role in cancer risk identification is three-fold. Despite the changes brought on by genetic/genomics, aspects of the nursing role are consistent with the essential competencies required of all professional nurses, according to a presentation at the 2015 Oncology Nurse Advisor Navigation Summit.
A new study indicates that the PD-1 protein pathway may niot be the only primary player in T cell exhaustion.
Genomic mapping of malignant pediatric adrenocortical tumors has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.
A new study links a well-known cell communication pathway called Notch to pilocytic astrocytoma (PA), one of the more common brain tumors found in children.
The molecular mail sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study presented at ASH. The findings may ultimately guide doctors in deciding which therapies are best for individual patients with myeloma.
Molecular tests are poised to become a part of the treatment guidelines for prostate cancer. These tests provide information that extends beyond just identifying the type of cancer a patient has; they can also help narrow down treatment options to those that offer the best outcomes for patients.
A new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas (TCGA) Research Network has identified markers of aggressive tumors, which could allow for improved targeted therapy.
Cytokine therapy enhances the activity of natural killer (NK) cells against tumors that lack the cell surface protein known as MHC class I, according to new research.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|